CN115052603A - Bi853520与化疗药物的联用 - Google Patents
Bi853520与化疗药物的联用 Download PDFInfo
- Publication number
- CN115052603A CN115052603A CN202180012434.1A CN202180012434A CN115052603A CN 115052603 A CN115052603 A CN 115052603A CN 202180012434 A CN202180012434 A CN 202180012434A CN 115052603 A CN115052603 A CN 115052603A
- Authority
- CN
- China
- Prior art keywords
- cancer
- tumor
- group
- chemotherapeutic agent
- pld
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ULMMVBPTWVRPSI-UHFFFAOYSA-N 2-fluoro-5-methoxy-4-[[4-[(2-methyl-3-oxo-1h-isoindol-4-yl)oxy]-5-(trifluoromethyl)pyrimidin-2-yl]amino]-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C(OC=3C=4C(=O)N(C)CC=4C=CC=3)C(=CN=2)C(F)(F)F)C(OC)=CC=1C(=O)NC1CCN(C)CC1 ULMMVBPTWVRPSI-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 239000002246 antineoplastic agent Substances 0.000 title claims description 56
- 229940044683 chemotherapy drug Drugs 0.000 title description 18
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 184
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims description 48
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 41
- 229960003668 docetaxel Drugs 0.000 claims description 41
- 229940127089 cytotoxic agent Drugs 0.000 claims description 37
- 206010033128 Ovarian cancer Diseases 0.000 claims description 33
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 33
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 26
- 206010017758 gastric cancer Diseases 0.000 claims description 26
- 201000011549 stomach cancer Diseases 0.000 claims description 26
- 229930012538 Paclitaxel Natural products 0.000 claims description 24
- 229960001592 paclitaxel Drugs 0.000 claims description 24
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 24
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 23
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 22
- 201000004101 esophageal cancer Diseases 0.000 claims description 22
- 229960004316 cisplatin Drugs 0.000 claims description 21
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 21
- 206010060862 Prostate cancer Diseases 0.000 claims description 19
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 19
- 229940123237 Taxane Drugs 0.000 claims description 17
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 14
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 201000005202 lung cancer Diseases 0.000 claims description 13
- 208000020816 lung neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- 229940095064 tartrate Drugs 0.000 claims description 8
- 229910052697 platinum Inorganic materials 0.000 claims description 7
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 6
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 206010057644 Testis cancer Diseases 0.000 claims description 6
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 201000000053 blastoma Diseases 0.000 claims description 6
- 201000008184 embryoma Diseases 0.000 claims description 6
- 201000007270 liver cancer Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000008968 osteosarcoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 201000002510 thyroid cancer Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002611 ovarian Effects 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 98
- 210000004027 cell Anatomy 0.000 description 63
- MFYYKSHXSCXFEA-UHFFFAOYSA-N 1-dodecyl-3-hydroxy-5-(hydroxymethyl)-2-methylpyridin-1-ium-4-carbaldehyde;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+]1=CC(CO)=C(C=O)C(O)=C1C MFYYKSHXSCXFEA-UHFFFAOYSA-N 0.000 description 54
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 description 48
- 230000037396 body weight Effects 0.000 description 34
- 230000000259 anti-tumor effect Effects 0.000 description 33
- 230000004614 tumor growth Effects 0.000 description 31
- 229940079593 drug Drugs 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- 238000012360 testing method Methods 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 19
- 230000003442 weekly effect Effects 0.000 description 19
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 16
- 230000004580 weight loss Effects 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000003111 delayed effect Effects 0.000 description 9
- 238000003304 gavage Methods 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 229940068196 placebo Drugs 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 8
- 229960004562 carboplatin Drugs 0.000 description 8
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 102100039788 GTPase NRas Human genes 0.000 description 7
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000011284 combination treatment Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 238000013411 master cell bank Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000013392 nude mouse xenograft model Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- -1 4- (2-methyl-3-oxo-2, 3-dihydro-1H-isoindol-4-oxy) -5-trifluoromethyl-pyrimidin-2-yl Chemical group 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- 208000012766 Growth delay Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000010972 statistical evaluation Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 150000003892 tartrate salts Chemical class 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000083700 Ambystoma tigrinum virus Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150073096 NRAS gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010071986 PTEN gene mutation Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 description 1
- 101150063858 Pik3ca gene Proteins 0.000 description 1
- 102100035202 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Human genes 0.000 description 1
- 101710114879 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 101150080074 TP53 gene Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 108700025694 p53 Genes Proteins 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
本发明涉及BI853520或其药学上可接受的盐在制备用于与化疗药物联用治疗肿瘤的药物中的用途。
Description
PCT国内申请,说明书已公开。
Claims (32)
- PCT国内申请,权利要求书已公开。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311560963.2A CN117599060A (zh) | 2020-02-05 | 2021-01-29 | Bi853520与化疗药物的联用 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010080757 | 2020-02-05 | ||
CN2020100807571 | 2020-02-05 | ||
PCT/CN2021/074371 WO2021155764A1 (zh) | 2020-02-05 | 2021-01-29 | Bi853520与化疗药物的联用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311560963.2A Division CN117599060A (zh) | 2020-02-05 | 2021-01-29 | Bi853520与化疗药物的联用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115052603A true CN115052603A (zh) | 2022-09-13 |
CN115052603B CN115052603B (zh) | 2023-12-19 |
Family
ID=77199643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180012434.1A Active CN115052603B (zh) | 2020-02-05 | 2021-01-29 | Bi853520与化疗药物的联用 |
CN202311560963.2A Pending CN117599060A (zh) | 2020-02-05 | 2021-01-29 | Bi853520与化疗药物的联用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311560963.2A Pending CN117599060A (zh) | 2020-02-05 | 2021-01-29 | Bi853520与化疗药物的联用 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20230079055A1 (zh) |
EP (1) | EP4101453A4 (zh) |
JP (1) | JP2023515765A (zh) |
KR (1) | KR20220137666A (zh) |
CN (2) | CN115052603B (zh) |
AU (1) | AU2021215747A1 (zh) |
BR (1) | BR112022015150A2 (zh) |
CA (1) | CA3165980A1 (zh) |
MX (1) | MX2022009612A (zh) |
WO (1) | WO2021155764A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023503897A (ja) * | 2019-11-18 | 2023-02-01 | ▲應▼世生物科技(南京)有限公司 | Nras変異を有する腫瘍を治療するための医薬品の調製におけるfak阻害剤の使用 |
JP2023515765A (ja) * | 2020-02-05 | 2023-04-14 | ▲應▼世生物科技(南京)有限公司 | Bi853520と化学療法薬の併用 |
MX2023001418A (es) * | 2020-08-03 | 2023-04-10 | Inxmed Nanjing Co Ltd | Forma sólida de compuesto. |
WO2023020291A1 (zh) * | 2021-08-16 | 2023-02-23 | 应世生物科技(南京)有限公司 | In10018与pld的联用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102292322A (zh) * | 2008-11-24 | 2011-12-21 | 贝林格尔.英格海姆国际有限公司 | 用于治疗例如癌症的疾病的取代的嘧啶 |
CN108289892A (zh) * | 2015-06-29 | 2018-07-17 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023503897A (ja) * | 2019-11-18 | 2023-02-01 | ▲應▼世生物科技(南京)有限公司 | Nras変異を有する腫瘍を治療するための医薬品の調製におけるfak阻害剤の使用 |
JP2023515765A (ja) * | 2020-02-05 | 2023-04-14 | ▲應▼世生物科技(南京)有限公司 | Bi853520と化学療法薬の併用 |
-
2021
- 2021-01-29 JP JP2022547735A patent/JP2023515765A/ja active Pending
- 2021-01-29 KR KR1020227028705A patent/KR20220137666A/ko active Search and Examination
- 2021-01-29 WO PCT/CN2021/074371 patent/WO2021155764A1/zh unknown
- 2021-01-29 MX MX2022009612A patent/MX2022009612A/es unknown
- 2021-01-29 CA CA3165980A patent/CA3165980A1/en active Pending
- 2021-01-29 US US17/797,867 patent/US20230079055A1/en not_active Abandoned
- 2021-01-29 AU AU2021215747A patent/AU2021215747A1/en active Pending
- 2021-01-29 BR BR112022015150A patent/BR112022015150A2/pt unknown
- 2021-01-29 CN CN202180012434.1A patent/CN115052603B/zh active Active
- 2021-01-29 EP EP21750093.3A patent/EP4101453A4/en active Pending
- 2021-01-29 CN CN202311560963.2A patent/CN117599060A/zh active Pending
-
2023
- 2023-07-05 US US18/347,324 patent/US20240024319A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102292322A (zh) * | 2008-11-24 | 2011-12-21 | 贝林格尔.英格海姆国际有限公司 | 用于治疗例如癌症的疾病的取代的嘧啶 |
CN108289892A (zh) * | 2015-06-29 | 2018-07-17 | 维瑞斯特姆股份有限公司 | 治疗组合物、组合和使用方法 |
Non-Patent Citations (2)
Title |
---|
医药观澜: "应世生物与默沙东达成全球临床合作,评估FAK抑制剂与帕博利珠单抗联合用药", pages 2 - 3, Retrieved from the Internet <URL:https://xueqiu.com/9766314542/138813166> * |
美通社: "应世生物FAK抑制剂IN10018中国一期临床试验获批", pages 4, Retrieved from the Internet <URL:https://www.prnasia.com/story/268783-1.shtm> * |
Also Published As
Publication number | Publication date |
---|---|
EP4101453A4 (en) | 2024-05-15 |
BR112022015150A2 (pt) | 2022-10-11 |
JP2023515765A (ja) | 2023-04-14 |
MX2022009612A (es) | 2022-09-19 |
EP4101453A1 (en) | 2022-12-14 |
CN117599060A (zh) | 2024-02-27 |
CA3165980A1 (en) | 2021-08-12 |
US20240024319A1 (en) | 2024-01-25 |
KR20220137666A (ko) | 2022-10-12 |
CN115052603B (zh) | 2023-12-19 |
WO2021155764A1 (zh) | 2021-08-12 |
US20230079055A1 (en) | 2023-03-16 |
AU2021215747A1 (en) | 2022-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115052603B (zh) | Bi853520与化疗药物的联用 | |
US7799783B2 (en) | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor | |
CN107001326B (zh) | 抗非小细胞肺癌的喹啉衍生物 | |
US20230398119A1 (en) | Combination therapy involving diaryl macrocyclic compounds | |
SG187828A1 (en) | Novel combination therapy for the treatment of cancer | |
CN111558044B (zh) | 一种包含舒尼替尼的药物组合物及其制剂和应用 | |
EP2754441A2 (en) | Composition for preventing and treating non-small cell lung cancer, containing pyrazino-triazine derivatives | |
TW201521742A (zh) | 具降低毒性之庫司替森(custirsen)療法 | |
CN113329749A (zh) | 用于治疗葡萄膜黑色素瘤的联合疗法 | |
CN112672789A (zh) | 用于治疗癌症的5-乙酰氨基甲基-噁唑烷酮衍生物 | |
CN111494385B (zh) | 一种治疗卵巢癌的药物及其制备方法和用途 | |
US20230038138A1 (en) | Combination therapy for treating cancer | |
US20240115582A1 (en) | Use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] for treating cancers | |
KR20150090091A (ko) | 볼라세르티브와의 병용 요법 | |
CN114288303B (zh) | 包含哌乙酰嗪的抗肿瘤药物组合物及其应用 | |
TW201728328A (zh) | 針對具有重度腎功能障礙之癌症患者之治療方法 | |
JP7450037B2 (ja) | 脳転移を有する末期非小細胞肺がん患者を治療するための組み合わせ医薬品 | |
EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
WO2024017316A1 (zh) | 药物组合产品以及组合疗法 | |
TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
CN112105361A (zh) | 用于治疗非小细胞肺癌的喹啉衍生物 | |
CN114787151A (zh) | 喹唑啉衍生物或其盐、或其药物组合物的用途 | |
JP2009108058A (ja) | 抗リンパ腫組成物および方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |